Abstract :
In order to address COVID-19 pandemic there has been efforts to advance potent neutralizing
mAbs against SARS-cov-2 as therapeutics. In this review we have summarized some of the leading mAbs
currently in development and present the evidence supporting inhaled delivery of antiviral mAbs as an early
intervention against COVID -19 that could prevent important pulmonary morbidities associated with the infection.
Highly potent mNAbs has great potential.To study SARS-CoV-2 antigenic drift under selective immune pressure
by mNAbs is important for the optimal implementation of mNAbs for the therapeutic management of COVID19.The use of monoclonal neutralizing antibodies (mNAbs) is being actively seeked as a viable intervention for
the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus
disease 2019 (COVID-19) .
Keyword :
SARS-CoV-2, COVID-19, Monoclonal antibodies, Treatment.